Technologieangebote

GBA2 – Therapeutic use of the non-lysosomal glucosylceramidase 2

Mutations in the lysosomal enzyme ß-glucosidase 1 (GBA1) cause Gaucher’s disease, the most common lysosomal lipid storage disease in humans. When GBA1 is absent or impaired, glycosylceramide (GlcCer) accumulates within the macrophage lysosomes, leading to liver and spleen enlargement, bone lesions and in the most severe cases, impairment of central

nervous system functions.

Weitere Informationen: PDF

PROvendis GmbH
Tel.: +49 (0)208/94105 10

Ansprechpartner
Dipl.-Ing. Alfred Schillert

Kommentare (0)

Schreiben Sie einen Kommentar